Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The macrolides.

Joseph M Blondeau¹, Emidio DeCarolis, Kelli L Metzler

¹Department of Clinical Microbiology, Saskatoon District Health and St. Paul's Hospital (Grey Nuns), Saskatoon, Saskatchewan, Canada. blondeauj@sdh.sk.ca

Expert Opinion on Investigational Drugs

|February 7, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative In Vitro Killing of Key Bovine Respiratory Bacterial Pathogens by Pradofloxacin and Eight Other Veterinary Antimicrobial Agents.

Microorganisms·2025

Same author

Bactericidal Activity of Pradofloxacin and Other Antimicrobials Against Swine Respiratory Bacterial Pathogens.

Pathogens (Basel, Switzerland)·2025

Same author

Effects of Comparative Killing by Pradofloxacin and Seven Other Antimicrobials Against Varying Bacterial Densities of Swine Isolates of <i>Pasteurella multocida</i>.

Microorganisms·2025

Same author

Retrospective analysis and clinical performance of BD MAX enteric pathogen testing with a focus on reliable identification of vibrio species in stool samples.

Diagnostic microbiology and infectious disease·2025

Same author

Long COVID: a consequence of chronic post-infectious inflammation!

Expert review of respiratory medicine·2024

Same author

Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of <i>Actinobacillus pleuropneumoniae</i> and <i>Pasteurella multocida</i>.

Molecules (Basel, Switzerland)·2024

Newer macrolides like azithromycin and clarithromycin offer improved pharmacokinetics and broader spectrums compared to erythromycin. Despite macrolide resistance, these agents remain crucial for managing infectious diseases.

Area of Science:

Microbiology
Pharmacology
Infectious Diseases

Background:

Erythromycin, the first clinical macrolide, had limitations due to pharmacokinetics and side effects.
The emergence of new pathogens and antimicrobial resistance necessitated the development of advanced antibiotics.
Azithromycin and clarithromycin represent enhanced macrolide structures.

Purpose of the Study:

To review the evolution of macrolide antibiotics.
To compare the properties of erythromycin with newer macrolides (azithromycin, clarithromycin).
To discuss the clinical utility and resistance patterns of macrolides.

Main Methods:

Literature review and analysis of clinical trial data.
Comparison of pharmacokinetic and pharmacodynamic profiles.

Related Experiment Videos

Evaluation of antimicrobial spectrum and resistance mechanisms.

Main Results:

Newer macrolides exhibit improved dosing frequency and reduced side effects.
Azithromycin and clarithromycin possess a broader spectrum, including atypical and resistant pathogens.
Macrolide resistance is a class effect, varying in level depending on the mechanism.

Conclusions:

Macrolides, particularly newer agents, are vital in treating diverse infectious diseases.
Despite resistance challenges, macrolides remain effective antimicrobial agents.
Specific indications may be limited to azithromycin or clarithromycin.